Nebulised magnesium sulphate v/s nebulised 2 percent lignocaine for attenuation of hemodynamic stress response to laryngoscopy and tracheal intubation: A prospective randomised double blinded ,comparative study - Nil

Start Date30 Aug 2024

Sponsor / Collaborator-

NCT04497766 / CompletedPhase 4IIT

Comparasion of Efficacy of Nebulized Magnesium Sulphate With Intravenous Magnesium Sulphate in Children With Acute Asthma

The purpose of study is to assess the effectiveness of nebulized magnesium sulphate in children presenting with acute asthma.Study perfoma consists of demographic variables,exclusion criteria and pediatric asthma score that includes respiratory rate,SPO2 at room air(requirement of oxygen),auscultatory findings in chest,dysnea and retractions.

Start Date01 Oct 2019

Sponsor / Collaborator

King Edward Medical University

[+1]

NCT04328636 / CompletedPhase 1/2IIT

Nebulized Magnesium Sulfate for Treatment of Persistent Pulmonary Hypertension of The Newborn

The aim of this pilot randomized controlled blinded study is to evaluate the feasibility of using nebulized magnesium sulfate in the treatment of PPHN.

Start Date01 Nov 2017

Sponsor / Collaborator

Sohag University

100 Clinical Results associated with Magnesium Sulfate Hydrate/Glucose

100 Translational Medicine associated with Magnesium Sulfate Hydrate/Glucose

100 Patents (Medical) associated with Magnesium Sulfate Hydrate/Glucose

Literatures (Medical) associated with Magnesium Sulfate Hydrate/Glucose

01 Sep 2022·Biological and Pharmaceutical Bulletin

Classification of Skin Injury Risk Caused by Extravasation of Electrolyte Solutions or Infusions in a Rat Model

Article

Author: Shibata, Yuuka ; Uno, Hiromi ; Yokooji, Tomoharu ; Matsuo, Hiroaki ; Hide, Michihiro ; Tanaka, Maiko ; Taogoshi, Takanori

Cytotoxic agents are classified according to the severity of skin injury after extravasation. However, injuries caused by extravasation of noncytotoxic agents have not been sufficiently investigated, although the risk of extravasation is mentioned in medical safety information published by the Japan Council for Quality Health Care. Therefore, in this study, we focused on noncytotoxic electrolyte solutions and infusions and evaluated skin injuries during leakage using extravasation model rats. Rats were anesthetized and intradermally injected with 100 µL of an electrolyte solution or infusion. Injection lesions were macroscopically and histopathologically evaluated for extravasation injuries. Each electrolyte solution and infusion were classified into three categories (vesicants, irritants, and non-tissue-damaging agents) depending on the degree of skin injury. Similar to saline, 0.3% potassium chloride and 0.6% magnesium sulfate showed almost no injury, and 3% sodium chloride and BFLUID^® caused erythema and induration. Erythema, induration, and ulceration were observed with the following: 10% sodium chloride, 2% calcium chloride, 8.5% calcium gluconate, 12.3% magnesium sulfate, MAGSENT^®, FESIN^®, and Intralipos^®. The duration of damage with these agents was markedly prolonged. Electrolyte solutions and infusions can be classified into vesicants (10% sodium chloride, 2% calcium chloride, 8.5% calcium gluconate, 12.3% magnesium sulfate, MAGSENT^®, FESIN^®, and Intralipos^®), irritants (3% sodium chloride and BFLUID^®), and non-tissue-damaging agents (0.3% potassium chloride and 0.6% magnesium sulfate) according to their composition. The characteristic symptoms and severity of each drug extravasation revealed in this study will provide basic information for preparation of guidelines for treatment of extravasation.

100 Deals associated with Magnesium Sulfate Hydrate/Glucose

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Eclampsia	JP	ASKA Pharmaceutical Co., Ltd.	25 Mar 2013
Eclampsia	JP	TOA Pharmaceuticals Co., Ltd.	25 Mar 2013
Obstetric Labor, Premature	JP	ASKA Pharmaceutical Co., Ltd.	23 Jan 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01515995 (CTgov)	Phase 4	Asthma	50	Nebulized magnesium sulfate (Magnesium Sulfate Group)	miibaeqavm(ixojlbdbou) = rjuazbplys vhxfyvxtgg (tclrllakpn, fbukypgres - dhzfkeigrx) View more	-	21 Feb 2019
				Nebulized magnesium sulfate (Normal Saline Group)	miibaeqavm(ixojlbdbou) = okoiynmtas vhxfyvxtgg (tclrllakpn, tlgunuaufl - nslbvxlhew) View more
Pubmed \| J Emerg Med	Not Applicable	Asthma	-	Nebulized magnesium sulfate plus albuterol	(jhmobzuwkq) = hslgxjfvem qxcusixbzm (ayglbjfvff )	Positive	01 Jul 2004
				Nebulized albuterol plus saline	(jhmobzuwkq) = anftnafxgl qxcusixbzm (ayglbjfvff )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Magnesium Sulfate Hydrate/Glucose

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation